Effect of MIST on Esophageal Sensitivity in Patients With rGERD (MIST)
Primary Purpose
Stress
Status
Recruiting
Phase
Not Applicable
Locations
Belgium
Study Type
Interventional
Intervention
MIST paradigm
Sham paradigm
Sponsored by
About this trial
This is an interventional other trial for Stress
Eligibility Criteria
Inclusion Criteria:
- Aged between 18 to 65 years;
Patients need to be classified as having gastroesophageal reflux disease and can be divided in three different groups (based on the Lyon consensus):
- True GERD: Acid exposure time (AET) >6% off PPI or >80 reflux episodes on PPI
- RHS: AET <4% off PPI or <40 reflux episodes on PPI and positive symptom association
- FH: AET <4% off PPI or <40 reflux episodes on PPI and negative symptom association --> Result based on a measurement maximum 1 year ago.
- Subjects must be capable of understanding and be willing to provide signed and dated written voluntary informed consent before any protocol-specific screening procedures are performed.
- Being able to stop PPI intake for 10 - 14 days before the study visit.
Exclusion Criteria:
- Endoscopic signs of severe erosive esophagitis (grade C or D, Los Angeles classification) on endoscopy performed off PPI treatment in the 12 months prior to screening, or ≥ grade B when endoscopy is performed on PPI treatment;
- Systemic diseases, known to affect esophageal motility (i.e. systemic sclerosis);
- Surgery in the thorax or in the upper part of the abdomen (appendectomy and cholecystectomy are allowed);
- Significant neurological, respiratory, hepatic, renal, hematological, cardiovascular, metabolic or gastrointestinal cerebrovascular disease as judged by the investigator;
- Severe anxiety/depressive disorder (assessed with the GAD7, PHQ9 and PHQ15);
- Medication intake that affect sensitivity: anti-depressants (selective serotonin re-uptake inhibitors and tricyclic antidepressants; SSRIs and TCA and daily use of benzodiazepines);
- Pregnancy or breastfeeding;
- History of alcohol or drug abuse that would interfere with ability to comply with protocol requirements.
Sites / Locations
- TARGIDRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Sham Comparator
Arm Label
MIST-paradigm
Sham-paradigm
Arm Description
Patients assigned to the MIST paradigm arm are exposed to psychosocial stress.
Patients assigned to the sham paradigm are not exposed to psychosocial stress.
Outcomes
Primary Outcome Measures
Esophageal mechanical sensitivity
Change in balloon distension
Esophageal chemical sensitivity
Change in time for reaching pain threshold
Secondary Outcome Measures
Cortisol levels
change in cortisol levels
Full Information
NCT ID
NCT05429034
First Posted
October 20, 2021
Last Updated
June 16, 2022
Sponsor
Universitaire Ziekenhuizen KU Leuven
1. Study Identification
Unique Protocol Identification Number
NCT05429034
Brief Title
Effect of MIST on Esophageal Sensitivity in Patients With rGERD
Acronym
MIST
Official Title
Effect of Acute Psychosocial Stress on Esophageal Sensitivity in Patients With Refractory Gastro-esophageal Reflux Disease
Study Type
Interventional
2. Study Status
Record Verification Date
June 2022
Overall Recruitment Status
Recruiting
Study Start Date
June 2022 (Anticipated)
Primary Completion Date
June 22, 2024 (Anticipated)
Study Completion Date
June 22, 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Universitaire Ziekenhuizen KU Leuven
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Effect of acute psychosocial stress on esophageal sensitivity in patients with refractory gastro-esophageal reflux disease and healthy volunteers.
Detailed Description
Gastro-esophageal reflux disease (GERD), defined as the presence of symptoms or lesions that can be attributed to the reflux of gastric contents into the esophagus, is an increasingly prevalent condition in Western societies. The most typical symptoms are heartburn and regurgitation, however GERD can also manifest itself through a variety of other esophageal and extra-esophageal symptoms (e.g. chronic cough).
GERD patients can be divided into different categories based on upper endoscopy and pH or impedance-pH (MII-pH) monitoring. In the absence of lesions (esophagitis) during upper endoscopy, a pH or MII-pH monitoring will be performed. A first subcategory are patients with true GERD, characterized by an abnormal acid exposure and a positive or negative symptom association. The second and third category are patients with reflux hypersensitivity (RHS) and functional heartburn (FH)characterized by normal acid exposure on the MII-pH monitoring and a positive and negative symptom reflux association, respectively.
The basis for symptom generation/perception in GERD patients is not yet completely understood, but different mechanisms have been proposed including esophageal hypersensitivity, in which psychosocial stress is considered as a potential factor. This was shown in a study where 64% of the participants with heartburn reported that psychological factors, such as life stress, aggravate their symptoms. Furthermore, Fass et al. observed that auditory stress exacerbated symptom perception during esophageal acid perfusion. Moreover, our group investigated the effect of intravenous corticotrophin releasing hormone (CRH) on esophageal in healthy volunteers and showed that CRH is able to increase esophageal sensitivity to mechanical distention. Nevertheless, these previously performed studies in patients have some limitations: no measurable increase in cortisol (hypothalamo-pituitary-adrenal (HPA)-axis was not affected in these studies) and patients with RHS and FH - in whom the effect of stress is hypothesized to be the most relevant - were not included.
To induce moderate psychologic stress in the current study, the Montreal Imaging Stress Task (MIST) will be used. During this protocol, participants receive mental arithmetic challenges, together with social evaluative threat components from the program and/or the investigator (sham condition: threat components from the program and/or the investigator are absent). This MIST protocol can be used when investigating the effects of perceiving and processing psychosocial stress in the human brain in functional imaging studies.
Therefore, the investigators want to investigate the relation between sensitivity to different stimuli (esophageal sensitivity) and psychosocial stress in healthy volunteers and patients (True GERD, RHS and FH).
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Stress
7. Study Design
Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
54 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
MIST-paradigm
Arm Type
Experimental
Arm Description
Patients assigned to the MIST paradigm arm are exposed to psychosocial stress.
Arm Title
Sham-paradigm
Arm Type
Sham Comparator
Arm Description
Patients assigned to the sham paradigm are not exposed to psychosocial stress.
Intervention Type
Behavioral
Intervention Name(s)
MIST paradigm
Intervention Description
Patients are exposed to psychosocial stress = receive mental arithmetic challenges, together with social evaluative threat components from the program and/or the investigator.
Intervention Type
Behavioral
Intervention Name(s)
Sham paradigm
Intervention Description
Patients are not exposed to psychosocial stress = threat components from the program and/or the investigator are absent
Primary Outcome Measure Information:
Title
Esophageal mechanical sensitivity
Description
Change in balloon distension
Time Frame
Assessed during visit 1 at time point 75 minutes
Title
Esophageal chemical sensitivity
Description
Change in time for reaching pain threshold
Time Frame
Assessed during visit 1 at time point 180 minutes
Secondary Outcome Measure Information:
Title
Cortisol levels
Description
change in cortisol levels
Time Frame
every 15 minutes a saliva sample during 4.5 hours: at time points (in minutes) 0, 15, 30, 45, 60, 75, 90, 105, 120, 135, 150, 165, 180, 195, 210, 225, 240, 255, 27
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Aged between 18 to 65 years;
Patients need to be classified as having gastroesophageal reflux disease and can be divided in three different groups (based on the Lyon consensus):
True GERD: Acid exposure time (AET) >6% off PPI or >80 reflux episodes on PPI
RHS: AET <4% off PPI or <40 reflux episodes on PPI and positive symptom association
FH: AET <4% off PPI or <40 reflux episodes on PPI and negative symptom association --> Result based on a measurement maximum 1 year ago.
Subjects must be capable of understanding and be willing to provide signed and dated written voluntary informed consent before any protocol-specific screening procedures are performed.
Being able to stop PPI intake for 10 - 14 days before the study visit.
Exclusion Criteria:
Endoscopic signs of severe erosive esophagitis (grade C or D, Los Angeles classification) on endoscopy performed off PPI treatment in the 12 months prior to screening, or ≥ grade B when endoscopy is performed on PPI treatment;
Systemic diseases, known to affect esophageal motility (i.e. systemic sclerosis);
Surgery in the thorax or in the upper part of the abdomen (appendectomy and cholecystectomy are allowed);
Significant neurological, respiratory, hepatic, renal, hematological, cardiovascular, metabolic or gastrointestinal cerebrovascular disease as judged by the investigator;
Severe anxiety/depressive disorder (assessed with the GAD7, PHQ9 and PHQ15);
Medication intake that affect sensitivity: anti-depressants (selective serotonin re-uptake inhibitors and tricyclic antidepressants; SSRIs and TCA and daily use of benzodiazepines);
Pregnancy or breastfeeding;
History of alcohol or drug abuse that would interfere with ability to comply with protocol requirements.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Annelies Geeraerts
Phone
+321643385
Email
annelies.geeraerts@kuleuven.be
Facility Information:
Facility Name
TARGID
City
Leuven
State/Province
Vlaams-Brabant
Country
Belgium
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Annelies Geeraerts
Phone
01643385
Email
Annelies.Geeraerts@kuleuven.be
12. IPD Sharing Statement
Learn more about this trial
Effect of MIST on Esophageal Sensitivity in Patients With rGERD
We'll reach out to this number within 24 hrs